Herantis Pharma Plc.

Herantis Pharma Plc. aloitti vaiheen Ib kliinisen tutkimuksen Parkinsonin taudissa raportointikauden aikana. Nykyisten rahavarojen pitäisi riittää vaiheen Ib valmistumiseen ja vaiheen II valmisteluun. Haastattelussa Herantiksen toimitusjohtaja Antti Vuolanto, haastattelijana analyytikko Antti Siltanen. (Interview in Finnish only): https://lnkd.in/d-qUnQjr #HerantisPharma #sijoittaminen

Watch Herantis Pharma Plc.’s FY 2024 webinar! https://lnkd.in/d22aAqSr #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology

"Herantis’ HER-096 program continued rapid progress during 2024: we achieved important partnerships with leading Parkinson’s charities, we started the Phase 1b clinical trial of HER-096, and the partnering discussions pharma industry have progressed with increasing interest towards HER-096. Obtaining financing of 3.6 million Euros from the two leading Parkinson’s charities to cover the costs of the Phase 1b trial, the Michael J. Fox Foundation and Parkinson’s UK, underlines the groundbreaking potential of HER-096. In the ongoing Phase 1b trial, HER-096 will be for the first time administered to people with Parkinson’s disease. Keeping in mind the promising results of the earlier CDNF Phase 1 trial, in which signs of both clinical and biological effects were seen in advanced Parkinson’s patients, we are now looking forward to the topline data expected in Q3 2025," said Antti Vuolanto, CEO of Herantis Pharma Plc. Read more https://lnkd.in/dDpzThqT #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology

Herantis Pharma Plc., a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease will webcast the 2H and Full Year 2024 results, Thursday March 6 at 14:30 EET (13:30 CET). The presentation will be held by CEO Antti Vuolanto and CFO Tone Kvåle, followed by a Q&A session.   Please use the following link to register for this event: https://lnkd.in/d22aAqSr   Read more here: https://lnkd.in/dQ__j5fv #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology

@Herantis Thank you, Ivo and Stop Parkinson organization! Ivo founded Stop Parkinson five years ago. He regularly organizes events to raise funds and increase awareness about the disease. “Five years ago, we started with a dream: to give hope to Parkinson’s patients. We continue to strive to support research that goes beyond just symptom relief. We want to enable therapies that can stop the disease,” Ivo says. €300,000 for Research Stop Parkinson Dilbeek is now donating €300,000 to research into HER-096, an innovative treatment for Parkinson’s disease. Around €150,000 was raised by Belgian donors in 2024, which was doubled thanks to a partnership with the Michael J. Fox Foundation for Parkinson’s Research. “Since our founding, we have been able to donate nearly two million euros to scientific research, thanks in part to the support of donors and partners,” says Ivo. HER-096, developed by the Finnish company Herantis Pharma, is a drug designed to slow the progression of Parkinson’s by protecting and restoring damaged dopamine-producing brain cells. Unlike traditional treatments that only address symptoms, HER-096 offers the potential for a disease-modifying therapy. The drug can be administered via a simple injection, making it a less invasive treatment for patients. Promising Clinical Studies “After promising results in safety studies with 60 healthy volunteers, HER-096 will now be tested on 24 people with Parkinson’s. Over four weeks, they will receive HER-096 or a placebo twice a week,” Ivo explains. “The study will provide crucial data on the drug’s safety and identify biomarkers that show how the body responds to the therapy.” “HER-096 is an innovative therapy that offers hope for breaking the status quo in Parkinson’s treatment,” says Dr. Femke Dijkstra, a neurologist at UZA and a member of Stop Parkinson’s medical team. “If this study is successful, it could be a game-changer in how we treat this disease. It’s exciting to be so close to a potentially groundbreaking breakthrough.” Ivo also cycled 450 kilometers this year for the cause. “We are thrilled to support the first clinical Herantis study together with the Michael J. Fox Foundation. We hope this research paves the way for a life-changing therapy for people with Parkinson’s,” Ivo concludes. Stop Parkinson Parkinson's UK The Michael J. Fox Foundation for Parkinson's Research

Dank aan Het Laatste Nieuws voor het delen van ons verhaal en het baanbrekende onderzoek dat we steunen! Dankzij de steun van zoveel donateurs en The Michael J. Fox Foundation for Parkinson's Research kunnen we 300.000 euro bijdragen aan een veelbelovend onderzoek naar HER-096, een mogelijke ‘gamechanger’ in de behandeling van de ziekte van Parkinson. Samen maken we een verschil! Blijf ons steunen en geef hoop aan duizenden patiënten. Doe een gift: https://lnkd.in/dJ7a8ctR Ivo de Bisschop Herantis Pharma Plc.

Dank aan Het Laatste Nieuws voor het delen van ons verhaal en het baanbrekende onderzoek dat we steunen! Dankzij de steun van zoveel donateurs en The Michael J. Fox Foundation for Parkinson's Research kunnen we 300.000 euro bijdragen aan een veelbelovend onderzoek naar HER-096, een mogelijke ‘gamechanger’ in de behandeling van de ziekte van Parkinson. Samen maken we een verschil! Blijf ons steunen en geef hoop aan duizenden patiënten. Doe een gift: https://lnkd.in/dJ7a8ctR Ivo de Bisschop Herantis Pharma Plc.

🚀 This Week in HealthHack: Digital therapy for endometriosis, new devices for Eczema relief, and how a company in Spain is tackling infections in fish farms. Read more below! From AI-driven hospital systems to programmable cell depletion that could transform disease treatment, this edition of HealthHack dives into the innovations shaping how we prevent, diagnose, and manage health conditions. We’re covering Lyv Healthcare’s digital therapy for endometriosis, new solutions for eczema relief, and even how genetic engineering is making biotech production scalable. Meanwhile, fish farm infections are getting a biotech fix, and hospitals are upgrading their IT systems to improve patient care. Whether you’re in the healthcare industry, a tech innovator, or just curious about the future of medicine, these breakthroughs highlight how science is making healthcare smarter, more accessible, and more personalised. This week’s highlights include advancements from Lyv, Enduro,Akribion Therapeutics, KOA Biotech, Avelios Medical, Cosi Care, Dxcover, neurocare group, Herantis Pharma Plc., Aplagon, and many more! 📩 Don’t miss out—subscribe to HealthHack for your weekly dose of cutting-edge health and biotech insights. #HealthTech #Innovation #HealthcareInnovation #Biotech #DigitalHealth #HealthHack https://lnkd.in/dmCiqVGr

The CEO of Herantis Pharma Plc., Antti Vuolanto, comments: "Thanks to this fundraising, we will be in a strong position when the topline data of the HER-096 phase 1b trial are released, which is expected in the third quarter of this year. We also continue the partnership discussions and preparations for the phase 2 trial. We thank our existing shareholders, who participated in this private placement, for their continued support in the development of HER-096 as a promising disease-modifying drug candidate for Parkinson’s disease, and we are happy to welcome new investors as the company's shareholders." Read more: https://lnkd.in/dGxaQnFZ #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology

The Herantis Pharma Plc. study takes place in Turku and Helsinki, Finland, conducted by the contract research organization Clinical Research Services Turku CRST